The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...
MedPage Today on MSN
FDA Halts Two Gene Therapy Trials After Child Develops Brain Tumor
Studies of Hunter and Hurler syndromes on hold ...
Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...
Clinical Trials Arena on MSN
FDA puts REGENXBIO gene therapy trials on hold after brain tumour
A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.
Jan 27 (Reuters) - Intellia Therapeutics said on Tuesday that the U.S. drug regulator has lifted a clinical hold on one of ...
University of California San Diego-led team has discovered that restoring a key cardiac protein called connexin‑43 in a mouse ...
The disease leads to the progressive growth of fluid-filled cysts in the kidneys, often resulting in kidney failure and other ...
When Genenta Science listed on the Nasdaq at the tail end of 2021, the Milan-based biotech was squarely focused on its pipeline of cell-based gene therapies. | Four years after listing on the Nasdaq, ...
Children with hereditary deafness regained their hearing thanks to a type of gene therapy, a new study published on Wednesday found. In a clinical trial, co-led by investigators from Mass Eye and Ear, ...
According to Nova One Advisor, the global cell and gene therapy manufacturing market size is reached at USD 26.67 billion in ...
After finding an intraventricular tumor in one clinical trial participant, the FDA placed a clinical hold on an experimental ...
The FDA suspends Regenxbio gene therapy trials for Hurler and Hunter syndromes over safety concerns after a participant developed a brain tumor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results